ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CBIO vs ARVN // NET PROFIT MARGIN

Crescent Biopharma Inc. (NASDAQ) VS. Arvinas Inc. (NASDAQ) • 15-METRIC TALLY: CBIO 3 — ARVN 3
▲ NET PROFIT MARGIN LEADER: CBIO
net-margins
1.40%
net-margins
-30.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CBIO VS. ARVN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CBIO ARVN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -32.10% -2.90 ARVN /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -13.86% — — TIE /fcf-yield <GO>
Operating Margin -60.00% -45.10% -14.90 ARVN /operating-margins <GO>
Net Profit Margin ACTIVE 1.40% -30.80% +32.20 CBIO /net-margins <GO>
Revenue Growth (YoY) — -0.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 6.36 0.20 +6.16 CBIO /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.1 54.6 -8.48 ARVN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $522.6M $516.6M $6.1M CBIO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CBIO REV ARVN REV CBIO GROSS % ARVN GROSS % CBIO FCF ARVN FCF
FY 2025 $10.8M $262.6M — — -$72.5M -$275.7M
FY 2024 $0 $263.4M — — -$31.1M -$261.1M
FY 2023 $0 $78.5M — — -$34.9M -$347.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CBIO // BETA —
ARVN // BETA —